Hepatitis b virus–specific t cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation

Journal of Clinical Investigation

Volumn 128, Issue 2, 2018, Pages 668-681

  Rivino, Laura ^a   Le Bert, Nina ^a,b   Gill, Upkar S ^a,c   Kunasegaran, Kamini ^a   Cheng, Yang ^d   Tan, Damien Z M ^b   Becht, Etienne ^d   Hansi, Navjyot K ^c   Foster, Graham R ^c   Su, Tung Hung ^e   Tseng, Tai Chung ^e   Lim, Seng Gee ^f   Kao, Jia Horng ^e   Newell, Evan W ^d   Kennedy, Patrick T F ^c   Bertoletti, Antonio ^a,b,d  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d AGENCY FOR SCIENCE   (Singapore)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PROGRAMMED DEATH 1 RECEPTOR; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS B VIRUS; HUMAN; MALE; MEDICAL HISTORY; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT WITHDRAWAL; VIRAL CLEARANCE; VIRUS CORE; VIRUS REPLICATION; AGED; BLOOD; CELL SEPARATION; COHORT ANALYSIS; CYTOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; COHORT STUDIES; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; T-LYMPHOCYTES; TENOFOVIR;

EID: 85041452586     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI92812     Document Type: Article

References (31)

1. Stanaway JD, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–1088.
2. Seeger C, Mason WS. Hepatitis B virus biology. MicrobiolMolBiolRev. 2000;64(1):51–68.
3. Höner Zu Siederdissen C, et al. Viral and host responses after stopping long-term nucleos (t) ide analogue therapy in HBeAg-negative chronic hepatitis B. JInfectDis. 2016;214(10):1492–1497.
4. Gill US, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015; 211(3):374–382.
5. Sheldon J, et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiret-roviral drugs with anti- HBV activity. J Acquir Immune Defic Syndr. 2007;46(3):279–282.
6. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. JHepatol. 2017;67(2):370–398.
7. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopou-los D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with ade-fovir. Gastroenterology. 2012;143(3):629–636.e1.
8. Berg T, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. JHepatol. 2017;67(5):918–924.
9. Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. JHepatol. 2016;64(1 Suppl):S71–S83.
10. Maini MK, Peppa D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front Immunol. 2013;4:57.
11. Boni C, et al. Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos (t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. Hepatology. 2015;62(6):1697–1709.
12. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612–616.
13. Tan AT, et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol. 2008;82(22):10986–10997.
14. Newell EW, Davis MM. Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells. Nat Biotechnol. 2014;32(2):149–157.
15. + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004;78(11):5707–5719.
16. Thimme R, et al. CD8 (+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. JVirol. 2003;77(1):68–76.
17. Boni C, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. JHepatol. 2003;39(4):595–605.
18. Tan AT, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol. 2010;52(3):330–339.
19. Becher B, et al. High-dimensional analysis of the murine myeloid cell system. Nat Immunol. 2014;15(12):1181–1189.
20. Blackburn SD, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29–37.
21. Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med. 2015;212(7):1125–1137.
22. Shi W, et al. Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections. InfectGenetEvol. 2013;16:355–361.
23. Seto WK, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut. 2015;64(4):667–672.
24. Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
25. Pallett LJ, et al. IL-2(high) tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. J Exp Med. 2017;214(6):1567–1580.
26. Boni C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. JVirol. 2007;81(8):4215–4225.
27. Evans A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology. 2008;48(3):759–769.
28. + versus CD8+ T lymphocytes in dengue virus infection. JVirol. 2013;87(5):2693–2706.
29. Wong MT, et al. Mapping the diversity of follicular helper T cells in human blood and tonsils using high-dimensional mass cytometry analysis. CellRep. 2015;11(11):1822–1833.
30. Finck R, et al. Normalization of mass cytometry data with bead standards. Cytometry A. 2013;83(5):483–494.
31. Amir el- AD, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013;31(6):545–552.